.Pharmacolibrary.Drugs.B_BloodAndBloodFormingOrgans.B01A_AntithromboticAgents.B01AF02_Apixaban.Apixaban .Pharmacolibrary.Drugs.B_BloodAndBloodFormingOrgans.B01A_AntithromboticAgents.B01AF02_Apixaban.Apixaban| name: | Apixaban |
| ATC code: | B01AF02 | route: | oral |
| n-compartments | 2 |
Apixaban is an oral, direct, selective factor Xa inhibitor anticoagulant used for the prevention and treatment of thromboembolic disorders such as stroke prevention in atrial fibrillation, treatment of deep vein thrombosis, and pulmonary embolism. It is an approved drug widely used in clinical practice.
Pharmacokinetic parameters are reported for healthy adult subjects, following a single oral dose administration.
Byon, W, et al., & Frost, CE (2019). Apixaban: A Clinical Pharmacokinetic and Pharmacodynamic Review. Clinical pharmacokinetics 58(10) 1265–1279. DOI:10.1007/s40262-019-00775-z PUBMED:https://pubmed.ncbi.nlm.nih.gov/31089975
Elenjickal, EJ, et al., & Mavrakanas, TA (2024). Anticoagulation in Patients with Chronic Kidney Disease. American journal of nephrology 55(2) 146–164. DOI:10.1159/000535546 PUBMED:https://pubmed.ncbi.nlm.nih.gov/38035566
Martin, KA, et al., & Moll, S (2017). Oral Anticoagulant Use After Bariatric Surgery: A Literature Review and Clinical Guidance. The American journal of medicine 130(5) 517–524. DOI:10.1016/j.amjmed.2016.12.033 PUBMED:https://pubmed.ncbi.nlm.nih.gov/28159600